Edition:
United Kingdom

Poxel SA (POXEL.PA)

POXEL.PA on Paris Stock Exchange

6.75EUR
4:35pm BST
Change (% chg)

€0.04 (+0.60%)
Prev Close
€6.71
Open
€6.70
Day's High
€6.79
Day's Low
€6.67
Volume
28,260
Avg. Vol
57,765
52-wk High
€8.18
52-wk Low
€5.19

Chart for

About

Poxel SAS is a France-based company principally engaged in the biopharmaceutical sector. The Company develops drugs with a focus on Type 2 diabetes. The Company aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication.... (more)

Overall

Beta: --
Market Cap(Mil.): €144.47
Shares Outstanding(Mil.): 22.93
Dividend: --
Yield (%): --

Financials

  POXEL.PA Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -0.96 -- --
ROI: -74.43 1.78 14.61
ROE: -76.50 3.29 16.33

BRIEF-Poxel FY Operating Loss Narrows To ‍​21.9 Million Euros

* FY OPERATING LOSS OF EUR ‍​21.9 MILLION VERSUS LOSS OF EUR 24.3 MILLION YEAR AGO

22 Mar 2018

Earnings vs. Estimates